GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Xcorporeal Inc (GREY:XCRP) » Definitions » EV-to-EBIT

Xcorporeal (Xcorporeal) EV-to-EBIT : 0.00 (As of May. 27, 2024)


View and export this data going back to . Start your Free Trial

What is Xcorporeal EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Xcorporeal's Enterprise Value is $0.00 Mil. Xcorporeal's EBIT for the trailing twelve months (TTM) ended in Sep. 2009 was $-9.29 Mil. Therefore, Xcorporeal's EV-to-EBIT for today is 0.00.

The historical rank and industry rank for Xcorporeal's EV-to-EBIT or its related term are showing as below:

XCRP's EV-to-EBIT is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 20.2
* Ranked among companies with meaningful EV-to-EBIT only.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Xcorporeal's Enterprise Value for the quarter that ended in Sep. 2009 was $1.95 Mil. Xcorporeal's EBIT for the trailing twelve months (TTM) ended in Sep. 2009 was $-9.29 Mil. Xcorporeal's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2009 was -476.60%.


Xcorporeal EV-to-EBIT Historical Data

The historical data trend for Xcorporeal's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xcorporeal EV-to-EBIT Chart

Xcorporeal Annual Data
Trend Feb99 Feb00 Dec01 Dec02 Dec03 Dec04 Dec05 Dec06 Dec07 Dec08
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -14.87 -7.20 6.04 -2.99 0.03

Xcorporeal Quarterly Data
Dec04 Mar05 Jun05 Sep05 Dec05 Mar06 Jun06 Sep06 Dec06 Mar07 Jun07 Sep07 Dec07 Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Xcorporeal's EV-to-EBIT

For the Medical Devices subindustry, Xcorporeal's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Xcorporeal's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Xcorporeal's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Xcorporeal's EV-to-EBIT falls into.



Xcorporeal EV-to-EBIT Calculation

Xcorporeal's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=0.000/-9.29
=0.00

Xcorporeal's current Enterprise Value is $0.00 Mil.
Xcorporeal's EBIT for the trailing twelve months (TTM) ended in Sep. 2009 adds up the quarterly data reported by the company within the most recent 12 months, which was $-9.29 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Xcorporeal  (GREY:XCRP) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Xcorporeal's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2009 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Sep. 2009 ) =EBIT / Enterprise Value (Q: Sep. 2009 )
=-9.29/1.949205
=-476.60 %

Xcorporeal's Enterprise Value for the quarter that ended in Sep. 2009 was $1.95 Mil.
Xcorporeal's EBIT for the trailing twelve months (TTM) ended in Sep. 2009 adds up the quarterly data reported by the company within the most recent 12 months, which was $-9.29 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Xcorporeal EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Xcorporeal's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Xcorporeal (Xcorporeal) Business Description

Traded in Other Exchanges
N/A
Address
80 Empire Drive, Lake Forest, CA, USA, 92630
Website
Xcorporeal Inc is a medical device company, developing an innovative extra-corporeal platform technology to be used in devices to replace the function of various human organs.
Executives
Kelly J. Mccrann director, officer: Chairman and CEO 11150 SANTA MONICA BLVD #1500, LOS ANGELES CA 90025
Daniel S Goldberger officer: Chief Executive Officer 24 CARPENTER ROAD, CHESTER NY 10918
Marc G Cummins director C/O PRIME LOGIC CAPITAL, LLC, 135 EAST 57TH STREET, 11TH FLOOR, NEW YORK NY 10022
Prime Logic Capital, Llc 10 percent owner 135 EAST 57TH STREET, 11TH FLOOR, NEW YORK NY 10022
Robert Weinstein officer: Chief Financial Officer 3960 HOWARD HUGHES PARKWAY, SUITE 500, LAS VEGAS NV 89169
Terren S Peizer director, 10 percent owner, officer: Executive Chairman 11111 SANTA MONICABLVD STE.500, LOS ANGELES CA 90025
Jay Wolf director 981 LINDA FLORA DRIVE, LOS ANGELES, CA 90049
Herve De Kergrohen director 22 CHEMIN DU NANTET, COLLONGE-BELLERIVE V8 CH1245
Nicholas Sheridan Lewin director 3 WEST 57TH ST., 8TH FLOOR, NEW YORK NY 10019
Lawrence Lacerte 10 percent owner C/O TERAGLOBAL COMMUNICATIONS CORP, 9171 TOWNE CENTRE DRIVE SUITE 600, SAN DIEGO CA 92122

Xcorporeal (Xcorporeal) Headlines